{{vm.title}}
25{{vm.includesText}}
{{item}}
{{vm.selectText}}
{{ vm.welcomeLabel.trim() }},
{{ vm.userName }}
{{ vm.text }}
{{vm.newUser1}} {{vm.newUser2}} {{vm.newUser3}} {{vm.newUser4}}
{{ vm.unknownUser }}
{{ vm.title }}
{{ vm.title }}
{{ vm.title }}
{{$store.state.data.search.serverData.config.placeholder}}
{{ vm.heading }}
{{ vm.closeTabLabel }}
Site Selection for Life Sciences Companies in Europe 2018
Site Selection for Life Sciences Companies
KPMG's 2018 report looks beyond site selection to include key work streams involved in successfully commercializing pharmaceutical products in Europe.
For Life Sciences companies looking to expand into Europe, there is a lot to think about. What is the best route to market, most effective launch sequence, and top location for a company’s specific specialization?
In the 2018 edition of KPMG’s Site Selection for Life Sciences Companies in Europe, we identify five key work streams involved in building a successful operating model. Our popular site selection analysis compares the attractiveness of different European countries, focusing on the most relevant factors such as innovation, infrastructure, taxation and incentives.
Watch our webcast or download the report below:
